A detailed history of J. Goldman & CO LP transactions in Replimune Group, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 70,637 shares of REPL stock, worth $871,660. This represents 0.02% of its overall portfolio holdings.

Number of Shares
70,637
Previous 136,050 48.08%
Holding current value
$871,660
Previous $1.22 Million 36.76%
% of portfolio
0.02%
Previous 0.04%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.09 - $11.23 $529,191 - $734,587
-65,413 Reduced 48.08%
70,637 $774,000
Q2 2024

Aug 14, 2024

BUY
$5.01 - $9.46 $681,610 - $1.29 Million
136,050 New
136,050 $1.22 Million
Q2 2023

Aug 14, 2023

SELL
$15.65 - $24.1 $729,336 - $1.12 Million
-46,603 Reduced 44.93%
57,120 $1.33 Million
Q1 2023

May 15, 2023

BUY
$17.48 - $29.09 $300,586 - $500,231
17,196 Added 19.87%
103,723 $1.83 Million
Q4 2022

Feb 14, 2023

BUY
$17.09 - $27.91 $1.48 Million - $2.41 Million
86,527 New
86,527 $2.35 Million

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $608M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track J. Goldman & CO LP Portfolio

Follow J. Goldman & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.